Emerson Collective Investments, Llc investment portfolio

Biomodal develops omics‑based life‑science technology and analytics products that provide single‑base‑resolution sequencing and multi‑omics solutions, extracting detailed genetic and epigenetic information from low‑input DNA samples. Its offerings serve researchers and developers working on cancer, neurodegenerative disease and ageing.

Genome Therapeutics Ltd develops novel chemical compounds, such as tetracyclic and quinolone derivatives, for use in antibody‑drug conjugates and other cancer‑targeted therapies. Its products are aimed at the pharmaceutical and biotechnology markets focused on oncology.